# Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)

> **NCT01303224** · PHASE2 · COMPLETED · sponsor: **Menarini Group** · enrollment: 565 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** Ibodutant
- **DRUG:** Ibodutant
- **DRUG:** Ibodutant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01303224
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 565 (ACTUAL)
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01303224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01303224, "Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01303224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*